An Observational Cohort Study to Explore the Clinical Outcome of Congenital Strabismmus Based on Etiology and Timing of Surgery
Launched by QIYU BO · Sep 24, 2024
Trial Information
Current as of April 02, 2025
Active, not recruiting
Keywords
ClinConnect Summary
Congenital esotropia, also known as infantile esotropia (IE), is a condition in which the eyes deviate inward at birth or within the first six months of life, with an incidence of 0.25%-0.50%. Its clinical features include a large angle of deviation with alternating gaze, the absence of binocular vision, and often accompanied by latent nystagmus, vertical disparity deviation, etc. Due to its early onset and constant nature, the damage to binocular vision function is more severe than that of other types of strabismus, and usually requires surgical correction of the eye position to improve th...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1) Children diagnosed with congenital esotropia and treated with surgery, regardless of gender; 2) Children aged 0-36 months; 3) The guardian of the patient voluntarily signs the informed consent.
- Exclusion Criteria:
- • 1) Esotropia found within 6 months of age due to anatomical abnormalities, extraocular muscle fibrosis, or paralysis or absence of nerves innervating the extraocular muscle; 2) There are diseases or structural abnormalities affecting ocular vision development, such as congenital cataract, congenital microeyeball, congenital glaucoma, genetic or blinding eye diseases with clear genetic mutations, such as Lerber amaurosis and ocular albinism; 3) Those deemed unsuitable for inclusion by the researchers.
About Qiyu Bo
Qiyu Bo is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative study design and rigorous scientific methodologies. With a focus on diverse therapeutic areas, Qiyu Bo collaborates with healthcare professionals and research institutions to conduct high-quality clinical trials that adhere to ethical standards and regulatory requirements. Their commitment to transparency, patient safety, and data integrity drives the development of new therapies, fostering a collaborative environment that enhances the efficiency and effectiveness of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported